Skip to main content

Table 2 Median proteasome subunit protein expression and NF-kB activity in paediatric acute leukaemia patients

From: Proteasome subunit expression analysis and chemosensitivity in relapsed paediatric acute leukaemia patients receiving bortezomib-containing chemotherapy

 

β5 (range)

β1 (range)

β5i (range)

β1i (range)

β5i/β5 (range)

β1i/β1 (range)

NF-kB activity

ALL

0.055 (0.01–0.76)

0.05 (0.01–0.86)

0.46 (0.06–3.43)

0.24 (0.07–1.45)

8.2 (0.66–94.5)

5.2 (0.18–64.7)

128.1 (11.8–1025.7)

 CR

0.045 (0.01–0.76)

0.05 (0.01–0.64)

0.47 (0.06–2.08)

0.31 (0.07–1.06)

8.55 (0.76–94.5)

6.8 (0.19–64.7)

253.5 (11.8–1022.2)

 No CR

0.065 (0.01–0.56)

0.1 (0.01–0.86)

0.38 (0.13–3.43)

0.22 (0.07–1.45)

6.7 (0.66–52.5)

3.4 (0.25–27.2)

73.0 (24.5–1025.7)

Pre-B ALL

0.04 (0.01–0.76)

0.04 (0.01–0.62)

0.46 (0.06–3.43)

0.33 (0.07–1.45)

11.4 (0.66–94.5)

7.1 (0.19–64.7)

90.2 (11.8–1025.7)

 CR

0.03 (0.01–0.76)

0.04 (0.01–0.62)

0.57 (0.06–2.08)

0.43 (0.07–1.06)

13.4 (0.76–94.5)

7.8 (0.19–64.7)

89.9 (11.8–1022.2)

 No CR

0.06 (0.01–0.49)

0.1 (0.01–0.32)

0.42 (0.13–3.43)

0.23 (0.12–1.45)

9.0 (0.66–52.5)

4.2 (0.7–27.2)

98.9 (24.5–1025.7)

T-ALL

0.12 (0.01–0.69)

0.11 (0.01–0.86)

0.44 (0.17–1.12)

0.21 (0.07–0.58)

3.9 (0.92–28.5)

1.77 (0.25–15.9)

333.7 (35.3–625.3)

 CR

0.21 (0.06–0.56)

0.1 (0.04–0.86)

0.37 (0.17–0.82)

0.11 (0.07–0.21)

1.78 (1.46–2.74)

1.1 (0.25–1.77)

393.5 (262.5–625.3)

 No CR

0.1 (0.01–0.69)

0.11 (0.01–0.64)

0.46 (0.18–1.12)

0.22 (0.16–0.58)

5.2 (0.92–28.5)

2.28 (0.33–15.9)

37.9 (35.3–40.5)

AML

0.12 (0.04–1.98)

0.13 (0.03–0.88)

0.41 (0.09–1.08)

0.17 (0.1–0.64)

3.2 (0.24–23.0)

1.97 (0.11–6.4)

524.5 (35.3–1323.7)

 CR

0.089 (0.04–0.21)

0.042 (0.031–0.26)

0.23 (0.09–0.92)

0.23 (0.13–0.64)

4.0 (0.45–23.0)

4.5 (2.4–6.3)a

804.1 (284.5–1323.7)

 No CR

0.13 (0.05–1.98)

0.18 (0.04–0.88)

0.52 (0.22–1.1)

0.16 (0.1–0.49)

3.2 (0.24–11.1)

0.94 (0.11–3.5)

524.5 (35.3–1246.5)

  1. Please note that Western blot data depict relative quantifications of subunit expression (ratio proteasome subunit/β-actin based on loading of 15 μg total protein, normalized to CEM). Quantifications were based on one Western blot analysis per sample. For three patients multiple replicate quantifications of subunits could be performed with a mean SD of <26 %. Lower limit of detection of protein bands quantification by Odyssey software; set to 0.01 AU for β5 and β1, 0.06 AU for β5i and 0.07 AU for β1i
  2. Pre-B ALL n = 45 patient samples for β5 and β5i, n = 43 for β1 and β1i, T-ALL n = 15 for β5 and β5i, n = 14 for β1 and β1i, AML n = 12 patient samples were used
  3. CR complete remission
Back to article page

Journal of Hematology & Oncology

ISSN: 1756-8722

Contact us